Treatment options for relapsed and refractory multiple myeloma

Clin Cancer Res. 2011 Mar 15;17(6):1264-77. doi: 10.1158/1078-0432.CCR-10-1805.

Abstract

Treatment options for patients with relapsed myeloma have benefited from the development of new targeted agents. The use of bortezomib, thalidomide, and lenalidomide have dramatically changed outcomes for patients with relapsed myeloma. New agents are also in development, on the basis of preclinical rationale, as well as combinations of conventional and novel agents. Together each of these treatment approaches are being tested in phase I, II, and III clinical trials, with the goal of prolonged duration of remission and, ultimately, improved overall survival.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Clinical Trials as Topic
  • Dexamethasone / administration & dosage
  • Drug Resistance, Neoplasm*
  • Humans
  • Lenalidomide
  • Medical Oncology / methods
  • Models, Biological
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Pyrazines / administration & dosage
  • Recurrence
  • Remission Induction
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives

Substances

  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Lenalidomide